To test whether PARPi administration could activate STAT3 in tumor-associated immune cells and thereby limiting PARPi efficacy by promoting immunosuppression directly through immune cells, we performed immunofluorescence staining of specific immune cell subsets from the same six ovarian cancer patients analyzed in Figure 1A. This evidence concerns the gene STAT3 and neoplasm.